#Odanacatib | Explore Tumblr Posts and Blogs

saradas-blog · 5 years

Text

Fármacos contra osteoporosis aumentan riesgos cardiovasculares

Especialistas recomiendan limitar su ingesta, ya que incrementan las posibilidades de padecer ataques al corazón o cerebrales en mujeres postmenopáusicas con osteoporosis

un cuando algunos medicamentos resultan beneficiosos en el tratamiento de la osteoporosis en mujeres postmenopáusicas, especialistas recomiendan limitar su prescripción pues su ingesta aumenta el riesgo de accidentes cardiovasculares.

De acuerdo con un grupo de investigadores encabezados por Michel R. McClung, medicamentos, como Odanacatib, inhiben la catepsina K, la cual reduce la resorción ósea -que vuelve a acoger un líquido que antes salió de su estructura- mientras mantiene la formación de hueso, pero incrementa las posibilidades de eventos cardiovasculares.

Un un artículo publicado en la revista The Lancet, Diabetes and Endocrinology, señalan que el fármaco reduce el riesgo de fractura, pero está asociado con un incremento en el riesgo de ataques al corazón o cerebrales, en mujeres postmenopáusicas con osteoporosis.

R. McClung explicó a partir de un estudio que incluyó a 388 pacientes en 40 países para medir la eficacia del medicamento a largo plazo, se comprobó que el medicamento evita que se humedezca el hueso, lo que aumenta las posibilidades de reparación del mismo, haciéndolo más fuerte.

Refirió que las participantes fueron mujeres de al menos 65 años, quienes presentan la postmenopausia de cinco años o más con condiciones óseas que permiten la ingesta del medicamento y de placebos para medir su efectividad; una parte de las participantes presentaban fracturas previas y otras no habían sufrido roturas de huesos.

Según el estudio, a las participantes en el estudio elegidas al azar se les aplicaron Odanacatib con dosis de 50 miligramos una vez por semana o un placebo idóneo.

Entre el 14 de septiembre de 2007 y el 17 de noviembre de 2009 la prueba fue aplicada a un mayor número de mujeres, a cuatro mil 297 les suministraron el medicamento, mientras que a tres mil 960 el placebo.

Al término del estudio se constató que, pese a que el Odanacatib ayuda al tratamiento de la osteoporosis en postmenopáusicas, su prescripción no es recomendable pues aumentan los accidentes cardiovasculares.

Descripción:

#https://www.excelsior.com.mx/nacional/farmacos-contra-osteoporosis-aumentan-riesgos-cardiovasculares/1348742

0 notes

azveille · 5 years

Text

Roche dumps early pipeline efforts as sales jump

Big Pharma giant Roche has quietly cut a series of early- to midstage experimental drugs as it continues the traditional quarterly clear-out. The most advanced of the cull was its midstage med petesicatib (RG7625), a selective small molecule antagonist of cathepsin S with “broad potential in inflammatory diseases,” according to Roche, that had been in tests as an immunosuppressant.

The target has history, being trialed predominately in osteoporosis. Six years ago, a cathepsin K inhibitor was the next big thing, with Merck especially touting it as a potential blockbuster.

But safety concerns nixed that in 2016 when its effort, odanacatib, appeared to increased stroke and other risks in those taking it. Combine this with only a modest efficacy, and it was duly tossed on the scrapheap.

It followed similar failed efforts from Novartis’ balicatib, canned because of bad skin reactions, and GlaxoSmithKline’s relacatib. Roche did not say why it chose to stop work on petesicatib.

There were also four phase 1 assets that have now been “removed,” according to its latest update: RG6148, an antibody-drug conjugate that consists of a monoclonal antibody targeting HER2-receptor; RG6123, an agent targeting the tumor-associated antigen carcinoembryonic antigen, with potential antineoplastic activity in solid tumors; RG6109, targeting acute myeloid leukemia; and RG6146, a small-molecule inhibitor of BET (bromodomain and extraterminal family), across a series of cancers.

As ever, little extra information has been given by the Swiss major on why it has removed these meds, though low efficacy/safety are always the surest bets.

The pipeline update came amid its third-quarter results, which saw pharma sales up 10% at constant exchange rates, boosted by new drugs coming through from its R&D.

0 notes

markengine-blog · 7 years

Text

Osteoporosis Drugs Market Global Industry Analysis, Pipeline Analysis,Trends & Forecast

Osteoporosis is a chronic and life-threatening disease, in which microstructure of bones is altered due to reduction in bone mass and bone density. This condition leads to increased bone fragility and threat of bone cracks and fractures. Thus, osteoporosis is considered life threatening due to severe injury and associated pain. The osteoporosis drugs market report studies the current scenario as well as the future market potential for osteoporosis drugs globally. The disease overview section of the report provides a brief introduction of osteoporosis along with causes, diagnosis, symptoms and management methodology. The market for osteoporosis drugs has been segmented on the basis of drug classes used to treat the disease. The market for these drug classes has been extensively analyzed on the basis of factors such as therapeutic application, geographic presence, pipeline drug candidates, patents and global impact on sales of the drugs (along with the class) after patent expiry. Based on drug class, the market is divided into bisphosphonates, calcitonin, RANK Ligand Inhibitors (denosumab), parathyroid hormone therapy (PTH), selective estrogen receptor modulators (SERMs) and others (estrogen therapy and vitamin D - calcium). Bisphosphonates is the largest and established drug class. However, the entire class is driven by generic products. Hence, market share of this class is expected to decrease during the forecast period from 2014 to 2020. In addition, new drug classes such as RANK Ligand Inhibitors and PTH are considered as important contributors in the market. Pipeline products such as odanacatib (cathepsin K inhibitor) and romosozumab are also forecasted from the expected year of approval. The market size and forecasts in terms of revenue (USD million) for each of these segments have been provided for the period 2012 to 2020, considering 2013 as the base year. The report also provides the compounded annual growth rate (CAGR) for each segment of the market for the forecast period 2014 to 2020.

Request For Sample Report: http://www.mrrse.com/sample/945

Geographically, the osteoporosis drugs market has been segmented into four regions: North America, Europe, Asia-Pacific and Rest of the World (RoW). The market size and forecast for each region has been provided for the period 2012 to 2020, along with the CAGR (%) for the forecast period 2014 to 2020. The geographical study is mainly based on various regional parameters, such as, prevalence of the disease in particular region, technological utilization, presence of key players, and other domestic factors. The study also includes qualitative analysis of the competitive scenario in these regions. The market overview section of the report comprises qualitative analysis of the overall market considering the factors determining the market dynamics such as drivers, restraints and opportunities, along with Porter’s five forces analysis, market attractiveness analysis, event impact analysis and value chain analysis. These different analyses would provide a thorough understanding about the market from its past, present and future perspectives and help market players to design effective business strategies. The market overview section of the report also includes the competitive landscape of the market wherein market share analysis of leading players in the global osteoporosis drugs market, in terms of percentage share in 2013, has been discussed. This analysis would help established players to penetrate the market. Market attractiveness analysis would help the market player to understand the level of attractiveness of various regions of the world, estimated on various parameters such as size, raw materials, competition and others.

A list of recommendations has also been included for new entrants as well as existing players to help establish a strong presence in the market and increase market share. The report concludes with the profiles of major players in the global osteoporosis drugs market such as Actavis plc, Amgen, Inc., Eli Lilly and Company, F. Hoffmann La Roche Ltd., Merck & Co, Inc., Novartis International AG, Novo Nordisk A/S, Pfizer, Inc., and Teva Pharmaceutical Industries Ltd.

Osteoporosis Drugs Market, by Drug Class

Bisphosphonates

Parathyroid Hormone Therapy (PTH) Drugs

Selective Estrogen Receptor Modulators (SERMs)

RANK Ligand Inhibitors

Calcitonin

Others (Vitamin D, Calcium)

Pipeline Analysis

Browse Full Reports With TOC : http://www.mrrse.com/osteoporosis-drug-market

Osteoporosis Drugs Market, by Geography

North America

Europe

Asia-Pacific

Rest of the World (RoW)

About Us

Market Research Reports Search Engine (MRRSE) is an industry-leading database of market intelligence reports. MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice. Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords.

MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSE’s repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.

Contact

State Tower 90, State Street Suite 700 Albany, NY - 12207 United States

Telephone: +1-518-730-0559 Email: [email protected]

Google+: https://plus.google.com/u/0/109558601025749677847/posts

Linked in: https://www.linkedin.com/company/mrrse

Twitter: https://twitter.com/MRRSEmrrse

0 notes